-
Your selected country is
Denmark
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Two-parameter flow cytometric analysis of CD317 (BST2) expression on Human peripheral blood leucocyte populations. Human whole blood was stained with either BD Horizon™ BV480 Mouse IgG2a, κ Isotype Control (Cat. No. 566089; Left Plot) or BD Horizon™ BV480 Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 568101/568102; Right Plot). Erythrocytes were lysed with BD FACS Lysing™ Solution (Cat. No. 349202). The pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.
Two-parameter flow cytometric analysis of CD317 (BST2) expression on Rhesus peripheral blood leucocyte populations. Rhesus whole blood was stained with either BD Horizon™ BV480 Mouse IgG2a, κ Isotype Control (Cat. No. 566089; Left Plot) or BD Horizon™ BV480 Mouse Anti-Human CD317 (BST2) antibody (Cat. No. 568101/568102; Right Plot). Erythrocytes were lysed with BD FACS Lysing™ Solution (Cat. No. 349202). The pseudocolor density plot showing the correlated expression of CD317 (BST2) [or Ig Isotype control staining] versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.
BD Horizon™ BV480 Mouse Anti-Human CD317 (BST2)
BD Horizon™ BV480 Mouse Anti-Human CD317 (BST2)
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- An isotype control should be used at the same concentration as the antibody of interest.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- BD Horizon Brilliant Violet 480 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- Species cross-reactivity detected in product development may not have been confirmed on every format and/or application.
- Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
Companion Products
The Y129 monoclonal antibody specifically binds to CD317 which is also known as Bone marrow stromal antigen 2 (BST2). CD317 is a type II transmembrane glycoprotein that belongs to the Tetherin family. CD317 is an interferon (IFN)-induced protein that is expressed on monocytes, granulocytes, dendritic cells, B lymphoblasts, plasma cells, T cells, natural killer (NK) cells, stromal cells and myeloma cells. CD317 is expressed by nonhematopoietic cells including cells within solid tumors derived from breast, lung and kidney. CD317 may be involved in the interactions between bone marrow stromal cells and lymphocytes. It is likewise known as Tetherin and reportedly blocks the release of some enveloped viruses by tethering virions to infected cell membranes. CD317 stimulates signaling by CD85g (ILT7) and may provide negative feedback for interferon (IFN) production by plasmacytoid dendritic cells during viral infections.
Development References (11)
-
Buckley CD, Halder S, Hardie D, et al. Report on antibodies submitted to the stromal cell section of HLDA8.. Cell Immunol. 236(1-2):29-41. (Immunogen). View Reference
-
Gong S, Osei ES, Kaplan D, Chen YH, Meyerson H. CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia.. Int J Clin Exp Pathol. 2015; 8(2):1613-21. (Biology). View Reference
-
Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells.. Blood. 1994; 84(6):1922-30. (Immunogen). View Reference
-
Harada T, Ozaki S. Targeted therapy for HM1.24 (CD317) on multiple myeloma cells.. Biomed Res Int. 2014; 2014:965384. (Clone-specific: Functional assay, In vivo exacerbation, Radioimmunoassay). View Reference
-
Mahauad-Fernandez WD, Okeoma CM. The role of BST-2/Tetherin in host protection and disease manifestation.. Immun Inflamm Dis. 2016; 4(1):4-23. (Biology). View Reference
-
Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.. Nature. 2008; 451(7177):425-30. (Biology). View Reference
-
Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT. Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV.. Cell Host Microbe. 2011; 9(1):46-57. (Clone-specific: Immunofluorescence). View Reference
-
Staudinger M, Glorius P, Burger R, et al. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.. Blood Cancer J. 2014; 4:e219. (Biology). View Reference
-
Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.. Cell Host Microbe. 2008; 3(4):245-52. (Clone-specific: Flow cytometry). View Reference
-
Vidal-Laliena M, Romero X, March S, Requena V, Petriz J, Engel P. Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell Immunol. 2005; 236(1-2):6-16. (Clone-specific: Calcium Flux, Flow cytometry). View Reference
-
Wiche Salinas TR, Gosselin A, Raymond Marchand L, et al. IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells.. iScience. 2021; 24(11):103225. (Clone-specific: Flow cytometry). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.